India's Jubilant Pharmova falls on FDA observations at Montreal unit
** Jubilant Pharmova JUBA.NS falls 2.5% to 1,152 rupees ** Pharmaceutical co says U.S. FDA issued nine observations in audit of co's facility in Montreal ** Stock rated "buy" on average; median PT is 1,384 rupees, per data compiled by LSEG ** YTD, JUBA rises 4.2% (Reporting by Mridula Kumar) ((Mridula.kumar@thomsonreuters.com))
Recent news on Jubilant Pharmova
See all newsBrief: Jubilant Pharmova Sept-Quarter Consol Net Profit 312 Million Rupees
Brief: Jubilant Pharmova Says Jubilant Therapeutics Announces Oral Presentation Of Preliminary Phase 1 Clinical Data For JBI-802
India New Issue-Jubilant Pharmova to issue 3-year bonds, bankers say
India's Jubilant Pharmova eyes $150 mln through rupee debt sale, bankers say
Brief: Jubilant Pharmova To Consider Raising Of Funds Through Issuance Of Non- Convertible Debentures